CAJ | 학술논문

目的　通过测定肝癌对阿霉素(ADM)、顺铂(DDP)、氟尿嘧啶(FU)、长春新碱(VCR)、丝裂霉素C(MMC)及噻替哌(TSPA)的体外药物敏感性，为肝癌化疗用药提供参考依据。方法　采用滤纸支持组织块培养-MTT终点-计算机图像分析体外药物敏感性试验法。结果　在1倍血浆峰浓度(1 PPC)时作用最强的药物为MMC，其抑制率中位数(MIR)为26.5%，其次是ADM为13.0%，DDP、TSPA、5-FU和VCR为4.0～8.5 %。在5倍血浆峰浓度(5 PPC)时作用最强的药物亦为MMC，其MIR为92.0%，次为ADM、DDP和TSPA为41～50%，5-FU和VCR为16.0～17.0%，DDP和TSPA在5 PPC的MIR比在1 PPC时大5.0和5.8倍以上，MMC、ADM和VCR则大2～3.5倍，5-FU只增大1倍左右。结论　结果提示MMC对肝癌抑制作用较强，DDP和TSPA剂量增加与疗效提高可能有较大的关系。天然来源的药物ADM、MMC和VCR之间，无论在1 PPC或5 PPC水平，其相关系数均较大(r=0.5539～0.7208)，表明部分肝癌具有多药耐药性。
목적　통과측정간암대아매소(ADM)、순박(DDP)、불뇨밀정(FU)、장춘신감(VCR)、사렬매소C(MMC)급새체고(TSPA)적체외약물민감성，위간암화료용약제공삼고의거。방법　채용려지지지조직괴배양-MTT종점-계산궤도상분석체외약물민감성시험법。결과　재1배혈장봉농도(1 PPC)시작용최강적약물위MMC，기억제솔중위수(MIR)위26.5%，기차시ADM위13.0%，DDP、TSPA、5-FU화VCR위4.0～8.5 %。재5배혈장봉농도(5 PPC)시작용최강적약물역위MMC，기MIR위92.0%，차위ADM、DDP화TSPA위41～50%，5-FU화VCR위16.0～17.0%，DDP화TSPA재5 PPC적MIR비재1 PPC시대5.0화5.8배이상，MMC、ADM화VCR칙대2～3.5배，5-FU지증대1배좌우。결론　결과제시MMC대간암억제작용교강，DDP화TSPA제량증가여료효제고가능유교대적관계。천연래원적약물ADM、MMC화VCR지간，무론재1 PPC혹5 PPC수평，기상관계수균교대(r=0.5539～0.7208)，표명부분간암구유다약내약성。
Objective　Through assessing the in vitro sensitivity of hepatoma to adriamycin (ADM), cisplatin (DDP), 5-fluorouracil (FU), vinscristine (VCR), mitomycin-C(MMC) and thiotepa (TSPA), reference for chemotherapy of hepatoma was provided.Methods　Tissue culture supported by filter paper-MTT endpoint-computer image analysis were employed in the in vitro drug sensitivity assay.Results　The median inhibition rate (MIR) at 1 time of peak plasma concentration (1 PPC) were 26.5 % for MMC, 13.0% for ADM, 4.0 %～8.5% for DDP, TSPA, FU and VCR. The MIR at 5 PPC were 92.0% for MMC, 41%～50% for ADM, DDP and TSPA, 16.0 %～17.0 % for FU and VCR. MIR of DDP and TSPA at 5 PPC was 5 times more than MIR at 1 PPC. Conclusion　The result of this experiment suggested that the most effect agent was MMC, and effect of DDP and TSPA were relative closely with the dose. Because the relative coefficient (r) between the agents from nature source, such as ADM, MMC and VCR, were larger (r=0.5539～0.7208) at either 1 PPC or 5 PPC, it is shown that some of hepatomas were multidrug resistant.